Service de Virologie et Mycobactériologie, CHU de Poitiers, Poitiers, France.
Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, UR 15560, Université de Poitiers, Poitiers, France.
AIDS Res Hum Retroviruses. 2022 Oct;38(10):779-781. doi: 10.1089/AID.2022.0058.
Doravirine (DOR) efficacy and safety have been evaluated in adult naive or treated patients starting a DOR-based regimen between September 15, 2019, and December 31, 2020. Medical history and examination, laboratory results, and tolerance were assessed during the 48 weeks of follow-up. Among the 77 patients included, virological control (VC) was noticed for 66 patients at baseline. Median age was 51 years, and 62% were men. The most common reason for initiating a DOR-based therapy was toxicity (44; 67%) and, especially, weight gain. A virological suppression (VS) was maintained in 55 (83%) patients of the VC group and noticed in 9 (82%) of the non-VC patients at week 48, by intention-to-treat analysis. On treatment analysis, 98% and 100% patients achieved VS in the VC and non-VC groups, respectively. The renal and metabolic tolerance were good. DOR-based regimens appear to be a safe and relevant strategy to circumvent drug interactions and drugs with a poor metabolic tolerance profile.
多伟拉韦（DOR）的疗效和安全性已在 2019 年 9 月 15 日至 2020 年 12 月 31 日期间开始接受 DOR 为基础方案治疗的初治或经治成年患者中得到评估。在 48 周的随访期间，评估了患者的病史和检查、实验室结果以及耐受性。在纳入的 77 例患者中，66 例患者在基线时存在病毒学控制（VC）。中位年龄为 51 岁，62%为男性。启动 DOR 为基础治疗的最常见原因是毒性（44 例；67%），尤其是体重增加。在 VC 组中，55 例（83%）患者维持了病毒学抑制（VS），在意向治疗分析中，48 周时，9 例（82%）非 VC 患者也出现了 VS。在治疗分析中，VC 组和非 VC 组分别有 98%和 100%的患者达到了 VS。肾和代谢耐受性良好。DOR 为基础的方案似乎是一种安全且相关的策略，可以规避药物相互作用和代谢耐受性差的药物。
AIDS Res Hum Retroviruses. 2022-10
Environ Sci Pollut Res Int. 2021-3
Clin Pharmacokinet. 2019-12
Zotero 插件